These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 28408301)

  • 21. miR-550a-3-5p acts as a tumor suppressor and reverses BRAF inhibitor resistance through the direct targeting of YAP.
    Choe MH; Yoon Y; Kim J; Hwang SG; Han YH; Kim JS
    Cell Death Dis; 2018 May; 9(6):640. PubMed ID: 29844307
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Wild-type KRAS is a novel therapeutic target for melanoma contributing to primary and acquired resistance to BRAF inhibition.
    Dietrich P; Kuphal S; Spruss T; Hellerbrand C; Bosserhoff AK
    Oncogene; 2018 Feb; 37(7):897-911. PubMed ID: 29059159
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma.
    Fofaria NM; Frederick DT; Sullivan RJ; Flaherty KT; Srivastava SK
    Oncotarget; 2015 Dec; 6(38):40535-56. PubMed ID: 26497853
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of BRAF Inhibitor Resistance-associated lncRNAs Using Genome-scale CRISPR-Cas9 Transcriptional Activation Screening.
    Wen X; Han M; Hosoya M; Toshima R; Onishi M; Fujii T; Yamaguchi S; Kato S
    Anticancer Res; 2024 Jun; 44(6):2349-2358. PubMed ID: 38821628
    [TBL] [Abstract][Full Text] [Related]  

  • 25. miR-126-3p down-regulation contributes to dabrafenib acquired resistance in melanoma by up-regulating ADAM9 and VEGF-A.
    Caporali S; Amaro A; Levati L; Alvino E; Lacal PM; Mastroeni S; Ruffini F; Bonmassar L; Antonini Cappellini GC; Felli N; Carè A; Pfeffer U; D'Atri S
    J Exp Clin Cancer Res; 2019 Jun; 38(1):272. PubMed ID: 31227006
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB.
    Rose AA; Annis MG; Frederick DT; Biondini M; Dong Z; Kwong L; Chin L; Keler T; Hawthorne T; Watson IR; Flaherty KT; Siegel PM
    Clin Cancer Res; 2016 Dec; 22(24):6088-6098. PubMed ID: 27515299
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SOX2-mediated upregulation of CD24 promotes adaptive resistance toward targeted therapy in melanoma.
    Hüser L; Sachindra S; Granados K; Federico A; Larribère L; Novak D; Umansky V; Altevogt P; Utikal J
    Int J Cancer; 2018 Dec; 143(12):3131-3142. PubMed ID: 29905375
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma.
    Nakamura A; Arita T; Tsuchiya S; Donelan J; Chouitar J; Carideo E; Galvin K; Okaniwa M; Ishikawa T; Yoshida S
    Cancer Res; 2013 Dec; 73(23):7043-55. PubMed ID: 24121489
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Cellular and molecular mechanisms of carcinogenic side effects and resistance to BRAF inhibitors in metastatic melanoma with BRAFV600 mutation: state of the knowledge].
    Capovilla M
    Ann Pathol; 2013 Dec; 33(6):375-85. PubMed ID: 24331719
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Leveraging transcriptional dynamics to improve BRAF inhibitor responses in melanoma.
    Smalley I; Kim E; Li J; Spence P; Wyatt CJ; Eroglu Z; Sondak VK; Messina JL; Babacan NA; Maria-Engler SS; De Armas L; Williams SL; Gatenby RA; Chen YA; Anderson ARA; Smalley KSM
    EBioMedicine; 2019 Oct; 48():178-190. PubMed ID: 31594749
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
    Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
    Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
    [TBL] [Abstract][Full Text] [Related]  

  • 32. E2F1/IGF-1R Loop Contributes to BRAF Inhibitor Resistance in Melanoma.
    Liu X; Mi J; Qin H; Li Z; Chai J; Li M; Wu J; Xu J
    J Invest Dermatol; 2020 Jun; 140(6):1295-1299.e1. PubMed ID: 31705876
    [No Abstract]   [Full Text] [Related]  

  • 33. Developments in the Space of New MAPK Pathway Inhibitors for BRAF-Mutant Melanoma.
    Cohen JV; Sullivan RJ
    Clin Cancer Res; 2019 Oct; 25(19):5735-5742. PubMed ID: 30992297
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Systemic treatment for BRAF-mutant melanoma: where do we go next?
    Menzies AM; Long GV
    Lancet Oncol; 2014 Aug; 15(9):e371-81. PubMed ID: 25079100
    [TBL] [Abstract][Full Text] [Related]  

  • 35. miR-410-3p is induced by vemurafenib via ER stress and contributes to resistance to BRAF inhibitor in melanoma.
    Grzywa TM; Klicka K; Paskal W; Dudkiewicz J; Wejman J; Pyzlak M; Włodarski PK
    PLoS One; 2020; 15(6):e0234707. PubMed ID: 32555626
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Noncanonical EphA2 Signaling Is a Driver of Tumor-Endothelial Cell Interactions and Metastatic Dissemination in BRAF Inhibitor‒Resistant Melanoma.
    Zhang C; Smalley I; Emmons MF; Sharma R; Izumi V; Messina J; Koomen JM; Pasquale EB; Forsyth PA; Smalley KSM
    J Invest Dermatol; 2021 Apr; 141(4):840-851.e4. PubMed ID: 32890629
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial.
    Chen G; McQuade JL; Panka DJ; Hudgens CW; Amin-Mansour A; Mu XJ; Bahl S; Jané-Valbuena J; Wani KM; Reuben A; Creasy CA; Jiang H; Cooper ZA; Roszik J; Bassett RL; Joon AY; Simpson LM; Mouton RD; Glitza IC; Patel SP; Hwu WJ; Amaria RN; Diab A; Hwu P; Lazar AJ; Wargo JA; Garraway LA; Tetzlaff MT; Sullivan RJ; Kim KB; Davies MA
    JAMA Oncol; 2016 Aug; 2(8):1056-64. PubMed ID: 27124486
    [TBL] [Abstract][Full Text] [Related]  

  • 38. miR-200c/Bmi1 axis and epithelial-mesenchymal transition contribute to acquired resistance to BRAF inhibitor treatment.
    Liu S; Tetzlaff MT; Wang T; Yang R; Xie L; Zhang G; Krepler C; Xiao M; Beqiri M; Xu W; Karakousis G; Schuchter L; Amaravadi RK; Xu W; Wei Z; Herlyn M; Yao Y; Zhang L; Wang Y; Zhang L; Xu X
    Pigment Cell Melanoma Res; 2015 Jul; 28(4):431-41. PubMed ID: 25903073
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Molecular background of BRAF inhibitor induced resistance in BRAFV600E mutant melanoma cell lines].
    Szász I; Koroknai V; Vízkeleti L; Balázs M
    Magy Onkol; 2021 Jun; 65(2):149-156. PubMed ID: 34081762
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug-induced expression of the RNA-binding protein HuR attenuates the adaptive response to BRAF inhibition in melanoma.
    Merat R; Bugi-Marteyn A; Wrobel LJ; Py C; Daali Y; Schwärzler C; Liaudet N
    Biochem Biophys Res Commun; 2019 Sep; 517(2):181-187. PubMed ID: 31279529
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.